Recent from talks
CoVLP
Knowledge base stats:
Talk channels stats:
Members stats:
CoVLP
CoVLP (brand name Covifenz) was a COVID-19 vaccine developed by Medicago in Canada and GlaxoSmithKline (GSK). The product and Medicago, Inc. were owned by Mitsubishi who terminated the company and program in February 2023 due to high international market competition for COVID-19 vaccines.
It is a coronavirus virus-like particle vaccine grown in the Australian weed, Nicotiana benthamiana.
The Medicago method to manufacture CoVLP was a "molecular farming" technology regarded as rapid, low-cost, and safe. It was proposed specifically for production of COVID-19 vaccines.
In February 2022, Health Canada authorized use of CoVLP for preventing COVID-19 infection in adults 18 to 64 years old. The authorization stated there was an efficacy rate of 71% after two vaccinations against symptoms of COVID-19 disease and 100% efficacy against severe COVID-19 infections.
On 7 December 2021, Medicago-GSK announced a preliminary analysis showing an overall efficacy of 71%, with 75% against the Delta variant and 89% efficacy against Gamma.
CoVLP is an example of a virus-like particle vaccine, consisting of a molecular complex which closely resembles a virus, but is non-infectious because it contains no viral genetic material. It uses recombinant spike proteins derived from SARS-CoV-2.
The virus-like particles are produced by creating a bacterium engineered with genes of the virus, then introducing the bacteria into Nicotiana benthamiana plants. The plants take up the bacteria virus-derived genetic material, producing in its leaves the virus-like particles, which are then harvested and extracted.
In use since the 1990s, the method of using a plant like N. benthamiana has been called "molecular farming" or a "plant-based factory", having vaccine manufacturing advantages of rapid, low-cost production of proteins, large scalability for production, and safety of using plants for pharmaceutical production. It has been proposed specifically for production of COVID-19 vaccines.
Hub AI
CoVLP AI simulator
(@CoVLP_simulator)
CoVLP
CoVLP (brand name Covifenz) was a COVID-19 vaccine developed by Medicago in Canada and GlaxoSmithKline (GSK). The product and Medicago, Inc. were owned by Mitsubishi who terminated the company and program in February 2023 due to high international market competition for COVID-19 vaccines.
It is a coronavirus virus-like particle vaccine grown in the Australian weed, Nicotiana benthamiana.
The Medicago method to manufacture CoVLP was a "molecular farming" technology regarded as rapid, low-cost, and safe. It was proposed specifically for production of COVID-19 vaccines.
In February 2022, Health Canada authorized use of CoVLP for preventing COVID-19 infection in adults 18 to 64 years old. The authorization stated there was an efficacy rate of 71% after two vaccinations against symptoms of COVID-19 disease and 100% efficacy against severe COVID-19 infections.
On 7 December 2021, Medicago-GSK announced a preliminary analysis showing an overall efficacy of 71%, with 75% against the Delta variant and 89% efficacy against Gamma.
CoVLP is an example of a virus-like particle vaccine, consisting of a molecular complex which closely resembles a virus, but is non-infectious because it contains no viral genetic material. It uses recombinant spike proteins derived from SARS-CoV-2.
The virus-like particles are produced by creating a bacterium engineered with genes of the virus, then introducing the bacteria into Nicotiana benthamiana plants. The plants take up the bacteria virus-derived genetic material, producing in its leaves the virus-like particles, which are then harvested and extracted.
In use since the 1990s, the method of using a plant like N. benthamiana has been called "molecular farming" or a "plant-based factory", having vaccine manufacturing advantages of rapid, low-cost production of proteins, large scalability for production, and safety of using plants for pharmaceutical production. It has been proposed specifically for production of COVID-19 vaccines.
Recent media